Antibe Therapeutics is a Toronto-based pharmaceutical research and development company developing inflammation-reducing drugs.[1] The conceived mechanism of action is to deliver a gaseous mediator, specifically hydrogen sulfide to sites of inflammation or injury within the human body. Hydrogen sulfide enhances the resolution of injury and repair of damage. Antibe was founded by John L. Wallace, co-founder of NicOx, the company that was the first to commercialize gaseous mediator technology. Antibe's board of directors includes Louis Ignarro, awarded the 1998 Nobel Prize in Physiology or Medicine for the basic research that underpins gaseous mediator technology, and Dr. Daniel K. Podolsky, Presient of the University of Texas Southwestern. Antibe's products have not yet been approved by the Food and Drug Administration. The lead drug, ATB-346, is a hydrogen sulfide-releasing derivative of naproxen, a commonly used non-steroidal anti-inflammatory drug. Unlike naproxen, ATB-346 does not induce damage in the gastrointestinal tract.